Proteostasis Therapeutics, Inc. (PTI) News

Proteostasis Therapeutics, Inc. (PTI)

Today's Latest Price: $1.05 USD

0.04 (3.96%)

Updated Nov 25 4:00pm

Add PTI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter PTI News Items

PTI News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest PTI News From Around the Web

Below are the latest news stories about Proteostasis Therapeutics Inc that investors may wish to consider to help them evaluate PTI as an investment opportunity.

PROTEOSTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Proteostasis Therapeutics, Inc. - PTI

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Proteostasis Therapeutics, Inc. (NasdaqGM: PTI) with Yumanity Therapeutics, Inc. in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction undervalues the Co

Business Wire | August 26, 2020

Proteostasis Therapeutics to merge with Yumanity Therapeutics

Proteostasis Therapeutics (PTI) and Yumanity Therapeutics Yumanity Therapeutics have entered into a definitive merger agreement.The combined company, operating under the name Yumanity Therapeutics, will leverage a common scientific expertise in the area of protein misfolding to advance its pipeline of disease-modifying programs for neurodegenerative diseases.Under the terms of agreement, PTI will acquire...

Seeking Alpha | August 24, 2020

Proteostasis Therapeutics Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its stockholders, employees and others, the Company is changing its 2020 Annual Meeting of Stockholders (the "Annual Meeting") to a virtual-only format that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.

Yahoo | June 5, 2020

3 “Strong Buy” Penny Stocks That Could See Outsized Returns

Which stocks tend to polarize market watchers? Penny stocks. Out on Wall Street, investors have strong opinions when it comes to these divisive tickers, which trade for less than $5 per share.The penny stock critics make valid points when defending their stance. Sure, the price tag may look like a steal, but the fact that shares are trading at such low levels could reflect overwhelming headwinds or weak fundamentals.That being said, the fans offer up a solid argument as well. Not only does the low price mean you get more shares for your money, but hefty returns are also on the table. Even seemingly insignificant share price appreciation can result in colossal percentage gains that other more well-known or expensive names aren’t as likely to deliver.The nature of these investments presen...

Yahoo | June 4, 2020

Proteostasis Therapeutics' PTI-129 a potential COVID-19 candidate

Proteostasis Therapeutics (PTI) is up 21% premarket after announcing results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19.PTI-129 is a pre-clinical, oral small molecule originally designed to treat protein misfolding disorders involving the unfolded protein response ((UPR)). In in vitro studies conducted at Calibr, the drug...

Seeking Alpha | June 1, 2020

Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19. PTI-129 is a pre-clinical, once-daily, oral small molecule originally designed to treat protein misfolding disorders involving the unfolded protein response (UPR).

Yahoo | June 1, 2020

Proteostasis Therapeutics (PTI) Reports Q1 Loss, Lags Revenue Estimates

Proteostasis (PTI) delivered earnings and revenue surprises of 17.39% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 15, 2020

Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that Proteostasis management will present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020 at 1:55 p.m. ET.

Yahoo | May 13, 2020

5 Top Stocks With Rising P/E to Bet On

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Yahoo | May 12, 2020

Will Proteostasis Therapeutics (PTI) Report Negative Q1 Earnings? What You Should Know

Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 6, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5696 seconds.